Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105104 | 1.00 | IDO1 (0.51) | IDO1PLA2G7MAOBTAAR1PNMT | |
| SCHEMBL9107180 | 0.88 | MAOB (0.47) | IDO1MAOBTAAR1PNMT | |
| SCHEMBL875395 | 0.88 | IDO1 (0.54) | IDO1PLA2G7MAOBRAF1BRAF | |
| SCHEMBL9901378 | 0.87 | IDO1 (0.49) | IDO1PLA2G7RAF1BRAFAR | |
| SCHEMBL9106976 | 0.87 | IDO1 (0.49) | IDO1PLA2G7RAF1BRAFAR | |
| SCHEMBL9905577 | 0.85 | PLA2G7 (0.48) | IDO1PLA2G7RAF1BRAFAR | |
| SCHEMBL29918301 | 0.85 | IDO1 (0.48) | IDO1PLA2G7RAF1BRAFAR | |
| SCHEMBL17226673 | 0.85 | IDO1 (0.48) | IDO1PLA2G7RAF1BRAFAR | |
| SCHEMBL875568 | 0.85 | IDO1 (0.48) | IDO1PLA2G7RAF1BRAFAR | |
| SCHEMBL875588 | 0.83 | IDO1 (0.51) | IDO1PLA2G7RAF1BRAFAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103347864-B | Pyrimidone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA 2 | 葛兰素集团有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2649053-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | IDO1 1163/4885PLA2G7 1/4885MAOB 356/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | IDO1 2560/4885PLA2G7 6/4885MAOB 991/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | IDO1 838/4885PLA2G7 4/4885MAOB 840/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | IDO1 2760/4885PLA2G7 2/4885MAOB 474/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | IDO1 884/4885PLA2G7 4/4885MAOB 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.